AI's Real Rx: Best-in-Class, Not Just First-in-Class
Genesis Molecular AI's Evan Fineberg argues AI's highest leverage isn't finding new targets, but designing superior drugs for 'undruggable' conditions and best-in-class therapies.
🔬 "The Most Innovative Diffusion Research Is Happening in Drug Discovery, Not Image Generation"
With R.J. Haniki, Brandon Anderson, Evan Fineberg, Sergey Udov · Sunday, July 5, 2026
This episode explores how Genesis Molecular AI is leveraging advanced AI, particularly diffusion models, to revolutionize drug discovery by achieving unprecedented accuracy in protein-ligand structure prediction. Guests Evan Fineberg and Sergey Udov discuss their Pearl model, the critical 1 angstrom resolution threshold, and their vision for AI agents automating drug discovery. They also delve into the challenges and opportunities of integrating wet lab data and reinforcement learning into their cutting-edge AI pipelines.
Genesis AI: Why Your "Good Enough" Metrics Are Broken
Founders, how precise are your core metrics? Genesis Molecular AI shows why sub-angstrom accuracy (1Å) is non-negotiable for drug discovery, and what that means for your business.